Last updated on December 2018

A Phase 3, Double-Blind, Randomized, 8-Week, Vehicle-Controlled Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Adolescents and Adults With Atopic Dermatitis


Brief description of study

This is a double-blind, randomized, 8 week, vehicle-controlled efficacy and safety study of Ruxolitinib cream followed by a long-term safety extension period in adolescents and adults with atopic dermatitis (eczema).

All enrolled subjects will receive a topical medication to be applied daily for 8 weeks. There are 9 in office visits throughout the study which may include a physical exam, blood draws, urine sampling, assessments by qualified professionals and other assessments which will be reviewed in detail at your screening visit.

At the end of the 8 week study period, participants will have the option to continue receiving treatment in a long-term extension study. All services are provided at no cost.

 

Detailed Study Description

  • Physical exam and assessments of study condition to be provided at no cost by an experienced provider.
  • No insurance necessary.
  • Compensation will be provided at the end of study participation.

 

Clinical Study Identifier: TX217809

Find a site near you

Start Over

Sadick Research Group

911 Park Avenue, Ste. 1A New York, NY United States
  Connect »